A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT01266811
Withdrawn
The purpose of this study is to determine if there is an improvement in progression-free survival (length of time during and after treatment in which a patient is living with a disease that does not get worse) when siltuximab is added to VELCADE and dexamethasone in subjects with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2013
Locations: Not set, Iowa City, Iowa +48 locations
Conditions: Multiple Myeloma
Register for Updates
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
NCT00663169
Completed
This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/04/2012
Locations: Novartis Investigator Site, Birmingham, Alabama +3 locations
Conditions: Arthritis, Gouty
Register for Updates
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
NCT00366834
Completed
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2012
Locations: GSK Investigational Site, Birmingham, Alabama +222 locations
Conditions: Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Register for Updates
A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
NCT00420849
Completed
This is a multi-centre, single-arm treatment study combining lenalidomide plus high dose dexamethasone. Subjects who qualify for participation will receive lenalidomide plus high dose dexamethasone in 4 week cycles. Subjects will be seen every 2 weeks for the first 3 cycles of therapy and then every 4 weeks after the third cycle until disease progression is documented, study drug is discontinued for any reason or lenalidomide becomes commercially available for this indication. Assessments of sa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2012
Locations: The Mater Private Centre for Haematology & Oncology, South Brisbane, Not set +4 locations
Conditions: Multiple Myeloma
Register for Updates
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
NCT00608907
Completed
The primary purpose of this Phase I study is to evaluate the effect of the co-administration of CYP3A4 inducers on the pharmacokinetics profile of VELCADE (bortezomib). Rifampicin will be used to assess the effect of a strong CYP3A4 inducer and dexamethasone to assess the effect of a relatively weak inducer. This study is also to evaluate the impact of CYP3A4 inducers on the pharmacodynamics (PD) of VELCADE and the safety profile of VELCADE.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/26/2012
Locations: Hematology Institute - Davidoff Center - Rabin Medical Center, Petach Tikva, Not set +8 locations
Conditions: Multiple Myeloma, Non-Hodgkin's Lymphoma
Register for Updates
Determinants of Corticosteroid Insensitivity in Smokers With Asthma
NCT00411320
Completed
Smokers with asthma display a relative insensitivity to inhaled and oral corticosteroids. The causes of this phenomenon are currently unknown. The investigators will perform a number of blood \& breathing tests to try to discover the cause/s behind this phenomenon with the aim of producing leads for further investigation and possible new treatments for smokers with asthma.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/03/2011
Locations: Asthma Research Unit, Glasgow University, Glasgow, Scotland
Conditions: Asthma, Smoking, Steroid Resistance, Corticosteroid Insensitivity
Register for Updates
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
NCT00333814
Completed
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2011
Locations: Not set, Dallas, Texas +17 locations
Conditions: Intermediate Uveitis, Posterior Uveitis
Register for Updates